-+ 0.00%
-+ 0.00%
-+ 0.00%

Anixa Biosciences Issues Update On Patient Outcomes Observed In Ongoing Phase 1 Ovarian Cancer CAR-T Clinical Trial, Following Regulatory Approval Of Protocol Amendment That Enables Substantial Dose Escalation

Benzinga·02/09/2026 13:09:17
Listen to the news

Multiple patients substantially exceed expected survival at low dose levels; absence of dose-

limiting toxicities supports escalation to doses up to 100x higher

Trial expansion reflects growing confidence in intra-peritoneal CAR-T delivery and introduces

lymphodepletion to potentially enhance efficacy

Anixa to participate in Water Tower Research fireside chat at 11:00am ET on February 10, 2026

to discuss trial observations

SAN JOSE, Calif., Feb. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment that enables substantial dose escalation.